Litigation Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)
✉ Email this page to a colleague
GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-03-14 |
Court | District Court, D. New Jersey | Date Terminated | 2019-05-15 |
Cause | 15:1126 Patent Infringement | Assigned To | Peter G. Sheridan |
Jury Demand | Plaintiff | Referred To | Tonianne J. Bongiovanni |
Parties | NATCO PHARMA INC. | ||
Patents | 7,964,580; 8,334,270; 8,580,765; 8,618,076; 8,633,309; 8,889,159; 9,085,573; 9,284,342; 9,549,941 | ||
Attorneys | KEITH J. MILLER | ||
Firms | Budd Larner, PC | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED
Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2018-03-14 | 1 | identifies the following patents as covering Sovaldi®: U.S. Patent Nos. 7,964,580; 8,334,270; 8,580,765;…expiration of U.S. Patent Nos. 8,618,076 (the “’076 patent”); 9,284,342 (the “’342 patent”); 7,429,572 (the…(the “’572 patent”); 8,415,322 (the “’322 patent”); 9,206,217 (the “’217 patent”); and 9,340,568 (the…. This is an action for patent infringement arising under the patent laws of the United States, …the “’568 patent”) (collectively, the “patents-in-suit”). | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |